Do peptides help with stroke recovery?
3 peptides are graded for stroke recovery on this page. The strongest grade is human RCT evidence, for cerebrolysin. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for stroke recovery?
Acute care in a stroke unit with thrombolysis or thrombectomy within their time windows; then early, intensive, multidisciplinary rehabilitation (physical, occupational, and speech therapy); secondary prevention with antiplatelet or anticoagulant therapy, statins, and blood pressure control.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for stroke recovery?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Cerebrolysin | Evidence: Human RCT evidence | CASTA (n = 1,070) missed its primary endpoint; CARS (n = 208) favored cerebrolysin on arm function at 90 days; a 2020 Cochrane review found no effect on death; not FDA approved. [1] [2] |
| Semax | Evidence: Human observational evidence | Unblinded Russian studies reported faster neurological recovery when added to standard care; approved in Russia only; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product. [4] [6] [8] |
| Noopept | Evidence: Human observational evidence | Improved cognitive test scores after two months in 60 stroke patients with mild cognitive impairment versus controls; a single Russian study. [5] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for stroke recovery?
Cerebrolysin has the strongest evidence among the peptides graded here, at human RCT evidence. CASTA (n = 1,070) missed its primary endpoint; CARS (n = 208) favored cerebrolysin on arm function at 90 days; a 2020 Cochrane review found no effect on death; not FDA approved. [1] [2]
Is any peptide FDA approved for stroke recovery?
No. None of the peptides graded for stroke recovery is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [7]
Has any peptide been tested in a randomized trial for stroke recovery?
Yes, for cerebrolysin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2]
From the blog
- Semax nasal spray: what the intranasal studies show
Semax was developed in Russia as nasal drops. What the intranasal stroke and imaging studies measured, how nasal and injected data compare, and what the July 2026 PCAC meeting means.
Sources
- [1]Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA)PubMed 22282884, 2012
- [2]Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trialPubMed 26564102, 2016
- [3]Cerebrolysin for acute ischaemic stroke (Cochrane review, 2020 update)PubMed 32662068, 2020
- [4]The efficacy of semax in the treatment of patients at different stages of ischemic strokePubMed 29798983, 2018
- [5]Noopept in the treatment of mild cognitive impairment in patients with strokePubMed 22500312, 2011
- [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [7]Drugs@FDA: FDA-approved drugs databaseFDA
- [8]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026